BOLT Bolt Biotherapeutics, Inc.

Nasdaq boltbio.com


$ 5.91 $ 0.00 (0 %)    

Thursday, 16-Oct-2025 15:59:15 EDT
QQQ $ 598.57 $ -5.24 (-0.87 %)
DIA $ 458.71 $ -3.77 (-0.81 %)
SPY $ 659.30 $ -6.23 (-0.93 %)
TLT $ 91.32 $ 0.85 (0.94 %)
GLD $ 396.85 $ 5.21 (1.33 %)
$ 6.005
$ 6.00
$ 5.55 x 100
$ 6.39 x 20
-- - --
$ 4.59 - $ 14.36
13,283
na
11.53M
$ -0.14
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-24-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-21-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-29-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-10-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-30-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-31-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 bolt-biotherapeutics-q2-eps-446-beats-627-estimate-sales-180m-beat-81975k-estimate

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.46) per share which beat the analyst consensus estimate of ...

 bolt-biotherapeutics-to-effect-1-for-20-reverse-stock-split

-SEC Filing

 lake-street-initiates-coverage-on-bolt-biotherapeutics-with-buy-rating-announces-price-target-of-4

Lake Street analyst Chad Messer initiates coverage on Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy rating and announces Pri...

 stifel-maintains-hold-on-bolt-biotherapeutics-lowers-price-target-to-1

Stifel analyst Stephen Willey maintains Bolt Biotherapeutics (NASDAQ:BOLT) with a Hold and lowers the price target from $1.2...

 bolt-biotherapeutics-q1-eps-029-beats-036-estimate-sales-122m-beat-76750k-estimate

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of ...

 bolt-biotherapeutics-announces-it-will-host-key-opinion-leader-conference-call-and-webcast-to-discuss-bdc-3042-phase-1-results-monday-may-12-2025-at-230-pm-pt--530-pm-et

Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET- Bolt Biotherapeutics (NASDAQ:BOLT), a biop...

 bolt-biotherapeutics-presents-preclinical-results-from-next-generation-boltbody-isacs-targeting-ceacam5-and-pd-l1-at-aacr-annual-meeting

CEA-targeted ISAC elicits complete responses in mice and is well-tolerated in NHPsPD-L1 ISAC directly activates and reprograms ...

 hc-wainwright--co-reiterates-neutral-on-bolt-biotherapeuticsto-neutral

HC Wainwright & Co. analyst Edward White reiterates Bolt Biotherapeutics (NASDAQ:BOLT) from Neutral to Neutral.

 stifel-maintains-hold-on-bolt-biotherapeutics-lowers-price-target-to-125

Stifel analyst Stephen Willey maintains Bolt Biotherapeutics (NASDAQ:BOLT) with a Hold and lowers the price target from $1.5...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION